Long-term Prospective CCM® Registry Results

678 views
July 21, 2021
The results of the largest prospective registry to date (503 patients followed for 3 years) for CCM therapy are in. Prof. Dr. Jürgen Kuschyk – the lead author of the publication – discusses the results and the implications of utilizing cardiac contractility modulation to affect NYHA functional class, quality of life, and perhaps most importantly the rate of heart failure and cardiac hospitalizations.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
0 Comments
Login to view comments. Click here to Login